Núcleo de Oncologia da Bahia

Salvador 40170170

0 studies enrolling now · 4 studies all time

What they study most

PD-L1 Negative, PD-L1 Positive, Pancreatic Cancer, Receptors, Fibroblast Growth Factor, Triple Negative Breast Cancer, Urothelial Cancer

Studies at this site

• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations — Completed
• Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine — Stopped early